Press Releases

RSS
  • Nov 30, 2015
    ENGLEWOOD, Colo., Nov. 30, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, will present at two upcoming investor conferences. Aytu is scheduled to present live at VirtualInvestorConferences.com, an interactive real-time virtual conference, to be held December 3, 2015, and at LD Micro's Main Eve...
    Nov 19, 2015
    ENGLEWOOD, Colo., Nov. 19, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, today announced that the Company will host a joint conference call with Ampio Pharmaceuticals (NYSEMKT: AMPE) to discuss the details of Ampio's previously announced intention to distribute most of its 11,626,068 shares o...
    Oct 22, 2015
    ENGLEWOOD, Colo., Oct. 22, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare company focused on urological and related conditions, presented encouraging clinical data from two prospective clinical studies of its MiOXSYS® System that demonstrated its clinical utility as a tool for measuring oxidation-reduction potential (ORP) to assess the degree of...
    Oct 6, 2015
    ENGLEWOOD, Colo., Oct. 6, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, today announced that it has acquired the rights to Primsol® (trimethoprim hydrochloride) oral solution from FSC Laboratories, Inc.  Primsol is the Company's second acquisition of a branded, revenue-generating p...
    Sep 28, 2015
    ENGLEWOOD, Colo., Sept. 28, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, today will host its inaugural quarterly conference call to review recent accomplishments and provide an overview of its business and growth strategy, as well as its financial results for the fiscal year ended Ju...
    Sep 21, 2015
    ENGLEWOOD, Colo., Sept. 21, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the Company will host its inaugural quarterly conference call on Monday, September 28, 2015, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its...
    Sep 16, 2015
    ENGLEWOOD, Colo., Sept. 16, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, will present new data at the American Society for Reproductive Medicine's annual meeting. The data are from a study utilizing Aytu's MiOXSYS™ System to measure oxidative stress levels in semen, which is broad...
    Sep 9, 2015
    ENGLEWOOD, Colo., Sept. 9, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today the appointment of Jonathan Heath McGrael as Vice President of Sales of Aytu Bioscience, effective September 16, 2015. Mr. McGrael has significant experience building healthcare sales organizatio...
    Sep 2, 2015
    ENGLEWOOD, Colo., Sept. 2, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that it has closed the final tranche of its planned private placement convertible note financing, raising a total of $5.175 million, which includes proceeds from two prior tranches totaling $3.175...
    Aug 13, 2015
    ENGLEWOOD, Colo., Aug. 13, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that its S-1 registration statement relating to the registration of 2,564,872 common shares owned by certain stockholders and issuable to certain warrant holders in Aytu's predecessor companies wa...